Abstract: An authentication server capable of determining securely and accurately whether an access source is a cellular phone or a computer when a content is accessed with being limited to cellular phone users.

Abstract: Provided is an acoustic measurement device capable of reducing the number of microphones while solving a problem of the dependency of interval between microphones on the frequency. The acoustic measurement device comprises a sound reception section (10) and a calculation section (20). The sound reception section includes a plurality of unidirectional microphones. The plurality of microphones of the sound reception section (10) are arranged such that the total sum of the unit vectors each facing the maximum sensitivity direction of the microphone is zero. The calculation section (20) calculates a particle velocity vector or acoustic intensity by multiplying respective unit vectors by measurement values of each of the plurality of microphones of the sound reception section and calculates acoustic information by vector-synthesizing the results.

Abstract: A motif is searched which can inhibit the proteolysis of a protein that has been administered to a cell or an individual. Thus, disclosed is a method for designing/producing a protein having resistance to proteolysis. Specifically disclosed is a motif capable of inhibiting proteolysis, which comprises an amino acid region lying between the 396th position and the 410th position from the C-terminal of DP-1.

Abstract: The present invention provides a therapeutic agent for epithelial and endothelial injury, and in particular, for epithelial and endothelial microinjury, and the like. The therapeutic agent according to the present invention comprises, for example, a peptide of the following (a), (b), etc., a derivative thereof, or their salt: (a) a peptide comprising the amino acid sequence shown in any one of SEQ ID NOS: 10, 4, 12 and 6; or (b) a peptide comprising the amino acid sequence shown in any one of SEQ ID NOS: 16, 18, 20 and 22.

Abstract: An objective of this invention is to provide an HCV strain with a high capacity for virus production in a cell culture system. This invention provides a nucleic acid encoding a polyprotein precursor of the hepatitis C virus JFH1 strain having one or more amino acid substitutions, wherein the polyprotein precursor comprises at least substitution of glutamine at position 862 with arginine, as determined with reference to the amino acid sequence as shown in SEQ ID NO: 2 in the Sequence Listing.

Abstract: A pharmaceutical composition for external use which is an organogel containing a fatty acid ester and a glycerolglycerin fatty acid ester, in particular, a novel transdermally absorbabedle pharmaceutical composition for external use which has a drug such as non-narcotic analgesics as an active ingredient made in organogel form containing a drug such as non-narcotic analgesics as an active ingredient, a fatty acid ester and a glycerolglycerin fatty acid ester, and a method for producing the composition. The pharmaceutical composition significantly improves skin permeability of drugs such as non-narcotic analgesics and allows a sufficient amount of drug to permeate the skin sustainably. Moreover, since the pharmaceutical composition is in organogel form, it can be easily applied to a preparation in practice. In addition, the pharmaceutical composition can provide efficient use and the like of drugs due to a high drug release rate and therefore is highly useful.

Abstract: An agent for treating malignant tumors based on a new mechanism is provided, which comprises an indirubin derivative represented by formula (1) or a salt thereof: wherein A represents an alkylene group having 1 to 4 carbon atoms, and R1 to R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, or an alkoxy group.

Abstract: An image processing device acquiring pseudo projection data by calculation when a virtual metallic body having a predetermined X-ray absorption coefficient is set in a photographic region of X-ray CT photography in a pseudo manner based on projection data, and the image processing device reconstructing the pseudo projection data to acquire pseudo CT image data. The image processing device acquires luminance (virtual metallic body luminance) of a virtual metallic body in the pseudo CT image data, and specifies a position of a metal equivalent region having luminance corresponding to the virtual metallic body luminance in normal CT image data. The image processing device acquires correction projection data by performing correction processing to the luminance of the metal equivalent region in the normal projection data, and the image processing device reconstructs the correction projection data to acquire correction CT image data.

Abstract: A pressure vessel structure includes a vessel main body, and a grid layer provided on a periphery of the vessel main body and including a plurality of grid lines formed by intersecting strip-form raw materials so as to overlap alternately. Thus, a burst pressure of the pressure vessel is increased.

Abstract: The present disclosure relates to a novel polyolefin having a terminal double bond and a method of producing the same. A polyolefin having a terminal double bond includes a polyolefin having a terminal double bond at either end and a polyolefin having a terminal double bond at one end, which are thermal degradation products of a polyolefin. An average number of terminal vinylidene groups per molecule is 1.3 to 1.9, a number average molecular weight (Mn) is 50,000 to 5,000,000, and a polydispersity index (Mw/Mn) of a molecular weight distribution is less than or equal to 5.0.

Abstract: Provided is a novel compound which simultaneously inhibits both NMDA receptors and ASIC1a, which are associated with neurodegenerative disease and so on, and thus is useful for the prevention and treatment of various nervous system diseases. A biguanide derivative represented by the following general formula (1), a salt thereof, or a hydrate of the derivative or the salt: wherein, X1 represents a halogen atom, R1 represents an alkyl group, an optionally substituted aryl group, or an optionally substituted aralkyl group.

Abstract: In an X-ray imaging apparatus that performs X-ray CT imaging, an X-ray generator (13) that generates an X-ray cone beam (BX1) and an X-ray detector (21) that detects the X-ray cone beam (BX1) radiated to an object (specifically, image object (OB)) are revolved for 180 degrees to be opposed to each other with the object being located therebetween. Further, the X-ray generator (13) is moved such that a revolution reference point (CP) that is set on an optical path (CB) of the X-ray cone beam (BX1) goes round of a predetermined oval shape while the X-ray detector (13) and the X-ray generator (21) are revolved for 180 degrees. Setting is made such that a CT image area (CA) to be imaged by the irradiation of the X-ray cone beam (BX1) has an approximately triangular shape through the above-mentioned operation.

Abstract: An acoustic energy measurement device that measures acoustic energy, the acoustic energy measurement device has a sound receiving unit that performs sound/electricity conversion and includes a plurality of unidirectional microphones being so disposed that a sum total of unit vectors facing a maximum sensitivity direction thereof becomes zero. The acoustic energy measurement device further includes a sound pressure calculation unit that calculates sound pressure using an output from the sound receiving unit. Still further, the acoustic energy measurement device has a particle velocity calculation unit that calculates particle velocity using an output from the sound receiving unit. Still further, the acoustic energy measurement device has an acoustic energy calculation unit that calculates acoustic energy using outputs from the sound pressure calculation unit and the particle velocity calculation unit.

Abstract: Provided is a hair oil that spreads smoothly, gives a soft and light finish, and satisfactorily effectively imparts a moist feel, easiness of styling, and a glossy feel to the hair. The provided hair oil includes an oil-based gel-like composition including a gel-forming agent and an oil-phase component, in which: the gel-forming agent includes a lecithin; and at least one selected from a polyglycerol and a polyglycerol fatty acid ester in an amount (total amount) of from 5 to 100 percent by weight per 100 percent by weight of the lecithin; the polyglycerol has a degree of polymerization of from 2 to 20; and the polyglycerol fatty acid ester has a fatty acid residue having 14 or less carbon atoms, has an HLB of 15 or more as calculated based on an organic conceptual diagram, and has a degree of polymerization of from 8 to 40.

Abstract: An agent for treating malignant tumors based on a new mechanism is provided, which comprises an indirubin derivative represented by formula (1) or a salt thereof: wherein A represents an alkylene group having 1 to 4 carbon atoms, and R1 to R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, or an alkoxy group.

Abstract: A compound having the general formula (I) or a pharmacologically acceptable salt thereof: X—NH—Y—NH—R1??(I) [wherein X represents R2—SO2— in which R2 represents an optionally substituted lower alkyl group or phenyl group; Y represents a group selected from the group consisting of —R3—NH—R4—, —R5—NH—R6—NH—R7—, —R8—NH—R9—NH—R10—NH—R11—and —R12—NH—R13—NH—R14—NH—R15— in which R3 to R15 each independently represent a C3 to C5 alkylene group; and R1 represents hydrogen or an optionally substituted lower alkyl group, with the proviso that the case where X represents a tosyl group, Y represents —(CH2)3—NH—(CH2)4—NH—(CH2)3—and R1 represents hydrogen is excepted].

Abstract: The present invention provides a sepsis therapeutic drug useful for prophylaxis and treatment of sepsis. A prophylactic agent and/or a therapeutic agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt of 5-ALA or the derivative as an active ingredient is prepared. The prophylactic agent and/or the therapeutic agent preferably contains a metal-containing compound such as ferrous sodium citrate in addition to the ALAs. Preferred examples of the ALAs include ALA; various esters of ALA such as methyl, ethyl, propyl, butyl, and pentyl esters; and hydrochlorides, phosphates, sulfates of ALA and the esters.

Abstract: Provided is a gel-forming agent that is easy to prepare and has all the properties including high safety for the living body and the environment, satisfactory gel-forming capability, comfortable feeling upon use, and good handleability. The gel-forming agent includes a lecithin, and a polyglycerol fatty acid ester in an amount of from 30 to 150 parts by weight per 100 parts by weight of the lecithin. The polyglycerol fatty acid ester has a fatty acid residue having 14 or less carbon atoms, has an HLB of 15 or more as determined based on an organic conceptual diagram, and has a degree of glycerol polymerization of from 8 to 40.

Abstract: A joining method includes punching respective laminated plate materials by a rivet shaft portion of a SPR, forming a crimp portion at the front end of the rivet shaft portion, and fastening and joining the laminated plate materials between the rivet head portion and the crimp portion. Washers are laid on and brought into contact with respective opposite surfaces relative to joining surfaces of the laminated plate materials, the washers each having an inner hole through which the rivet shaft portion is allowed to pass, the washers are used as jigs at the time of the punching, the punching by means of the rivet shaft portion is performed along the inner holes of the washers, and the joining is performed so that the washers left between the rivet head and the crimp portion and the opposite surfaces.

Abstract: The present invention provides a cell migration regulator capable of promoting or inhibiting cell migration, a method for regulating cell migration, and a pharmaceutical composition comprising such a regulator, etc. The cell migration regulator of the present invention comprises a peptide, a derivative thereof, or a salt of the peptide or the derivative, wherein the peptide comprises the full-length blood coagulation factor IX, a segment derived from the full-length blood coagulation factor IX by removal of the trypsin domain, the light chain of blood coagulation factor IX, or the EGF1 domain of blood coagulation factor IX, or the EGF3 domain of the endothelial cell locus-1 protein.